Boston therapeutics initiates new clinical study of bti-320 other otc bthe database crud

LAWRENCE, Mass., May 22, 2018 (GLOBE NEWSWIRE) — Boston Therapeutics Inc. (the “ Company” or “ BTI”) (OTCQB:BTHE), an innovator in the design, development and commercialization of novel therapeutics for diabetes and related complications, announces the start of a new study that will assess the potential of the investigative material for reducing the risk of strokes and diabetes in high risk Chinese with pre-diabetes. The objective of this proof-of-concept is to establish a non-invasive way to self-screen and manage pre-diabetes in a safe and effective manner.

BTI-320 has been shown to decrease post-meal glucose excursions (publication in press) and it is hypothesized that BTI-320 may help stall or delay the progression of diabetes and related complications, such as stroke. This study is designed to access the feasibility of predicting health risks from delaying the onset of diabetes as measured by the ARIA system.


The proprietary ARIA (Automated Retinal Imaging Analysis) technology was developed by Prof. Benny Zee at the Chinese University of Hong Kong. The extensive database will be licensed to Boston Therapeutics to build-on and expand continuously, where the analytics will be kept as a growing science in the field of public health, disease treatment and drug development. CEO Carl W Rausch commented: "We especially appreciate the support of the Innovation and Technology Commission in Hong Kong. It is helping foster the collaboration between public academic institutions and private companies." The site initiation meeting for the ARIA and BTI-320 study (Protocol: SJH-SG-HK01) was held on 4/27/18 in preparation for active enrollment by June 2018. This study received IRB approval in late March 2018 and is supported through a grant by the Innovation and Technology Commission in Hong Kong.

Boston Therapeutics, headquartered in Lawrence, MA (OTCQB:BTHE) and with an office in Albuquerque, NM is an innovator in design, development and commercialization of novel compounds to treat diabetes and diabetes related complications. The company has proprietary compounds based on glucose chemistry, peptide chemistry and protein conjugates.

This press release includes forward-looking statements. These statements may be identified by words such as "feel," "believes," expects," "estimates," "projects," "intends," "should," "is to be," or the negative of such terms, or other comparable terminology. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from the forward-looking statements contained herein. Factors that could cause actual results to differ materially include, but are not limited to: our limited operations and need to expand in the near future; risks associated with obtaining regulatory approval of our products; the ability to protect our intellectual property; the potential lack of market acceptance of our products; potential competition; our inability to retain key members of our management team; our inability to raise additional capital to fund our operations and business plan; our ability to continue as a going concern; our liquidity and other risks and uncertainties and other factors discussed from time to time in our filings with the Securities and Exchange Commission ("SEC"), including our annual report on Form 10-K filed with the SEC. Boston Therapeutics expressly disclaims any obligation to publicly update any forward-looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law.

banner